On November 3, 2021 Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, reported that the Company will be presenting three poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) annual meeting, to be held in Washington, D.C. and in a virtual platform, on November 10-14, 2021 (Press release, Inhibrx, NOV 3, 2021, View Source [SID1234594290]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share some of the preclinical data related to our clinical candidates, INBRX-105 and INBRX-106, which inform the selection of pharmacodynamic biomarkers, dosing and clinical strategy," said Brendan Eckelman, Ph.D., Inhibrx Co-founder and Chief Scientific Officer.
"Additionally, we will be introducing the first emerging pipeline candidate from our targeted cytokine platform, INBRX-121, which specifically expands and enhances the cytotoxic capacity of NK cells."

Poster Presentation Details:

Title: INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors
Lead Author: Emily Rowell, Ph.D.
Category: Novel Single-Agent Immunotherapies
Abstract: 856
Session Date & Time: ePoster on display beginning Friday, November 12th; 7:00 a.m. EST

Title: INBRX-105- Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist
Lead Author: Heather Kinkead, Ph.D.
Category: Biomarkers, Immune Monitoring, and Novel Technologies
Abstract: 12
Session Date & Time: Saturday, November 13th; 7:00 a.m.- 8:30 p.m. EST

Title: INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities
Lead Author: Florian J. Sulzmaier, Ph.D.
Category: Immune-Stimulants and Immune Modulators
Abstract: 722
Session Date & Time: Saturday, November 13th; 7:00 a.m.- 8:30 p.m. EST

The scientific posters will be accessible through the following link on the investors section of Inhibrx’s website at View Source

On November 3, 2021 Integral Molecular, an industry leader in developing antibodies against membrane proteins, reported that it entered into an exclusive worldwide antibody license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop therapeutics for multiple cancers (Press release, Integral Molecular, NOV 3, 2021, View Source [SID1234594289]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of highly specific monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.

"This agreement with Integral Molecular will allow AstraZeneca to generate additional novel cancer therapies and advance our goal of delivering personalised treatments to improve patient outcomes," said Mark Cobbold, VP, Discovery, Oncology R&D at AstraZeneca. "These antibodies can be incorporated into a number of therapeutic modalities and align with AstraZeneca’s ongoing pursuit of high-quality innovation to deliver life-changing treatments that increase the potential for cure."

"Specificity is incredibly important for therapies designed to eliminate cancer cells, since mistargeting can have serious safety ramifications for patients," said Benjamin Doranz, CEO and co-founder of Integral Molecular. "Our program has produced antibodies with picomolar affinity and high specificity even against conserved targets that have proven difficult to generate antibodies against. The specificity of these antibodies is a testament to the dedication and efforts of our talented team."

The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular’s platforms designed to yield antibodies against structurally complex membrane proteins. Together, the MPS Antibody Discovery platform, Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity.

On November 3, 2021 ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, reported the acceptance of six poster presentations on its lead development programs at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting (SITC 2021), which will be held November 10-14, 2021, in Washington, DC. Additional meeting information can be found on the SITC (Free SITC Whitepaper) website (Press release, ImmunoGenesis, NOV 3, 2021, View Source [SID1234594287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details

Posters Related to IMGS-001: PD-L1/PD-L2 Dual-Specific Antibody with Effector Function

Title: Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1
Poster Number: 233
Date: November 12, 2021

Title: Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity
Poster Number: 291
Date: November 12, 2021

Posters Related to IMGS-501: STING Immune Stimulating Antibody Conjugate (STING-ISAC)

Title: High-potency synthetic STING agonists rewire the myeloid stroma in the tumor microenvironment to amplify immune checkpoint blockade efficacy in refractory pancreatic ductal adenocarcinoma
Poster Number: 758
Date: November 13, 2021

Title: Intratumoral delivery of high potency STING agonists modulates the immunosuppressive myeloid compartment and induces curative responses in checkpoint-refractory Glioblastoma models
Poster Number: 763
Date: November 12, 2021

Posters Related to Evofosfamide Hypoxia-Reversal Agent in Combination with Checkpoint Inhibitors

Title: Disrupted oxygen supply and tumor hyper- oxygen consumption contribute independently to prostate cancer immune privilege
Poster Number: 622
Date: November 13, 2021

Title: Hypoxia reduction in tandem with anti-angiogenic therapy remodels the PDAC microenvironment and potentiates CD40 agonist therapy
Poster Number: 730
Date: November 13, 2021

On November 3, 2021 Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, reported that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with sarcoma (Press release, Sumitomo Dainippon Pharma, NOV 3, 2021, View Source [SID1234594286]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 open-label study consists of two parts, dose escalation and dose expansion. The dose escalation portion of the study established the maximum tolerated dose (MTD) and recommended Phase 2 Dose (RP2D) of TP-1287 in patients with advanced metastatic or progressive solid tumors. The dose expansion portion of the study will evaluate the potential antitumor activity and safety of TP-1287 in patients with Ewing sarcoma (EWS), dedifferentiated liposarcoma (DDLPS) and synovial sarcoma (SS).

"Patients with sarcoma currently face a significant unmet need and have limited treatment options. The dose expansion of TP-1287 provides an opportunity for us to evaluate this treatment and its potential benefits for this patient population," said Patricia S. Andrews, Chief Executive Officer, Global Head of Oncology, Sumitomo Dainippon Pharma Oncology, Inc (SDP Oncology). "Furthermore, this is an important step forward for our Phase 1 trial as we continue to evaluate TP-1287’s safety and efficacy."

The primary objective of the Phase 1 dose expansion portion of the study is to evaluate the preliminary antitumor activity of TP-1287 in terms of objective response rate (ORR) when administered at the RP2D in patients with sarcoma subtypes. The secondary objectives are to determine the progression-free survival (PFS), PFS rate at 16 weeks and PFS rate at 24 weeks following first administration of TP-1287 in patients with the defined sarcoma subtypes and evaluate the safety of TP-1287 when administered at the RP2D in patients with the defined sarcoma subtypes.

The study is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT03604783).

About TP-1287

TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.1 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and c-MYC, an important oncogene across multiple tumor types.2,3,4 TP-1287 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (NCT03604783).

On November 3, 2021 Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will participate in the following virtual investor conferences (Press release, Insmed, NOV 3, 2021, View Source [SID1234594285]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Credit Suisse 30th Annual Virtual Healthcare Conference on November 9, 2021 at 10:30 a.m. ET in a fireside chat
The Stifel 2021 Virtual Healthcare Conference on November 17, 2021 at 8:40 a.m. ET in a fireside chat
The Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021 at 8:00 a.m. ET in a fireside chat
Each fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.